Active immunotherapy with dendritic cell vaccination in GB has been observed since 1999, demonstrating reduced tumor growth, prolonged survival, and antigen-specific cytotoxic T-CD8+ lymphocyte responses in murine models and early-stage clinical trials [33,34,35,36,37]. This evidence concerns the gene CD8A and neoplasm.